A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Clinical trial NCT03573323 · COMPLETED

Trial details

NCT number: NCT03573323
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2018-11-09
Primary completion: 2019-07-15
Enrollment: 1027

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.